Cartesian Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RNAC | CABA | AUTL | ALLO | FATE | 2126.HK | |
|---|---|---|---|---|---|---|
| Market cap | 206.34M | 240.75M | 367.30M | 411.13M | 250.42M | 1.11B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.8 | -1.2 | -2.2 | -1.9 | -2.2 | -3.0 |
| Price/book | -1.6 | 1.1 | 4.9 | 0.9 | 1.6 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −16.43% | −45.59% | +2.17% | +0.90% | +87.16% | −29.57% |
| Today | +6.40% | 0.00% | −2.47% | +6.25% | +2.45% | +7.91% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RNAC news ›Evotec SE : RBC gives a Buy rating
Charles Weston from RBC retains his positive opinion on the stock with a Buy rating. The target price is reduced from EUR 10 to EUR 5. Biotechnology & Medical Research Evotec SE : RBC gives a Buy rating
Piper Sandler Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Lexicon Pharmaceuticals today and set a price target of $6.00. According to TipRanks, Rahimi is a 5-star analyst with an average return of 23.0% and a 39.26% success rate.…
Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as Buy by HC Wainwright
Posted by Danessa Lincoln on Oct 28th, 2026 Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Wednesday, Benzinga reports. Get Our…
Recent Analysts’ Ratings Changes for Candel Therapeutics (CADL)
Several brokerages have updated their recommendations and price targets on shares of Candel Therapeutics (NASDAQ: CADL) in the last few weeks: 10/22/2026 – Candel Therapeutics is now covered by Jefferies Financial Group. They set a “buy”…
Canaccord Genuity Keeps Their Buy Rating on Voyager Therapeutics (VYGR)
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Voyager Therapeutics yesterday and set a price target of $12.00. The company’s shares closed yesterday at $3.20. Kulkarni covers the Healthcare sector, focusing on stocks…
Bicara Therapeutics’ (BCAX) Buy Rating Reaffirmed at BTIG Research
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report issued on Monday, Benzinga reports. They presently have a $39.00 price objective on the stock. BTIG…
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright
Posted by Danessa Lincoln on Oct 18th, 2026 HC Wainwright reissued their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a…
Eton Pharmaceuticals (NASDAQ:ETON) Stock Keeps Buy Rating at HC Wainwright
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $70.00 price target on the stock.…
Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)
Barclays analyst Etzer Darout maintained a Buy rating on First Tracks Biotherapeutics Inc today and set a price target of $65.00. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and Summit…
Cortexyme : BofA Securities Upgrades Cortexyme to Buy from Neutral
Cortexyme has an average rating of outperform and price targets ranging from $14 to $84, according to analysts polled by Capital IQ. Price: 40.66, Change: +2.12, Percent Change: +5.50 ... Biotechnology & Medical Research Cortexyme : BofA…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com8
- defenseworld.net5
- markets.businessinsider.com5
- marketscreener.com4
- marketbeat.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.